INTRODUCCIÓN: REVISIÓN CRITICA DEL PROBLEMA

RESULTADOS
0.007) and kidney failure (79.2 ± 19.8 vs 54.8 ± 13.3 AU, p = 0.001). sRAGE levels
werehigher in patients with ischemic CHF (1,321.1 = 1,105.2 vs 895.8 ± 596.5
pg/ml, p = 0.036) and kidney failure (1,545.2 ± 1,142.8 vs 1,039.5 ± 717.7 pg/ml, p
= 0.014). sRAGE levels were also significantly higher in severe than in mild CHF
(1,663.2 ± 1,135.9 vs 1,090.3 ± 770.6 pg/ml for New York Heart Association
classes III to IV vs I to II, respectively, p = 0.007). A significant inverse correlation
existed between plasma levels of AGE and sRAGE with hemoglobin and
creatinine (Figure 1). NT–pro-BNP correlated directly with fluorescent AGE (r =
0.226, p = 0.040) but not with sRAGE (Figure 1). Fluorescent AGE and sRAGE
showed a positive correlation (r = 0.283, p = 0.003).
Characteristics
Age (years)
Total
n = 106
72.0 (63.0-78.5)
TABLE 1. Baseline characteristics
Survivors
n = 95
69.6 ± 11.7
Nonsurvivors
n = 11
74.2 ± 9.8
P
0.233
No events
n = 77
68.0 ± 12.2
With events
n = 29
75.5 ± 7.4
Female 32.7% 34.0% 20.0% 0.368 33.8% 29.6% 0.693
IMC (Kg/m 2 ) 28.2 ± 4.4 28.4 ± 4.3 25.8 ± 4.4 0.202 28.5 ± 4.2 27.7 ± 4.7 0.678
Dyslipidemia 48.2% 52.7% 50.0% 0.869 50.0% 59.3% 0.419
Diabetes 35.8% 35.8% 36.4% 0.970 33.8% 41.4% 0.466
Hypertension 53.6% 57.6% 60.0% 0.884 53.3% 70.4% 0.124
NYHA III-IV
22.2% 21.3% 30.0% 0.533 19.2% 30.8% 0.222
Ischemic etiology 32.0% 30.1% 50.0% 0.200 25.0% 51.9% 0.010
Depressed LVEF
61.9% 63.6% 44.4% 0.259 63.9% 56.0% 0.484
eGFR < 60 ml/min 37.9% 37.6% 40.0% 0.883 30.3% 59.3% 0.008
Haemoglobin (g/dL) 13.1 ± 1.6 13.2 ± 1.5 11.7 ± 1.9 0.003 13.4 ± 1.5 12.4 ± 1.8 0.007
HDL-colesterol (mg/dL) 42.9 ± 17.8 43.9 ± 18.3 33.3 ± 8.5 0.091 45.0 ± 19.3 36.9 ± 11.3 0.139
LDL-cholesterol
110.2 ± 35.4 112.3 ± 34.2 87.8 ± 41.5 0.061 113.3 ± 31.1 100.4 ± 45.6 0.056
(mg/dL)
Glucose (mg/dL) 121.5 ± 43.4 122.6 ± 44.4 111.8 ± 33.0 0.458 118.6 ± 36.9 130.2 ± 58.9 0.254
Glycated haemoglobin 6.3 ± 1.3 6.3 ± 1.2 6.5 ± 2.1 0.709 6.2 ± 1.1 6.6 ± 1.6 0.146
Fluorescent AGE (a.u.) 67.3 ± 22.6 66.3 ± 21.4 76.5 ± 30.8 0.156 62.3 ± 19.0 80.6 ± 26.2 0.001
sRAGE (pg/mL) 1229.1 ± 931.4 1170.0 ± 909.6 1739.2 ± 1005.9 0.055 997.4 ± 766.2 1844.1 ± 1058.4 0.001
NT-proBNP (pg/mL) 2669.8 ± 3274.5 2356.2 ± 3139.0 5609.7 ± 3242.3 0.007 1971.8 ± 2944.1 5020.9 ± 3308.3 0.001
SHFS
Treatment:
ACEI/ARB-2
Beta-blockers
Diuretics
Statins
Insulin
7.3 ± 5.1 13.5 ± 10.7 6.6 ± 3.5 0.057 11.2 ± 7.6 5.8 ± 2.6 0.001
88.7%
85.1%
82.2%
41.7%
10.4%
89.6%
84.6%
80.2%
41.7%
10.4%
80.0%
90.0%
100.0%
50.0%
10.0%
0.315
0.543
0.127
0.427
0.723
0.9%
86.5%
75.7%
41.6%
7.8%
82.8%
81.5%
100.0%
44.8%
17.2%
ACEI: ARB-2: IMC: Body Mass Index. HDL:High Density Lipoprotein. LDL: Low Density Lipoprotein. LVEF: Left Ventricular Ejection
Fraction. NYHA: New York Heart Association. SHFS: Seattle Heart Failure Score
95
P
0.001
0.198
0.367
0.002
0.465
0.144